Dataset Information

Machine learning and glioma imaging biomarkers.

ABSTRACT: AIM:To review how machine learning (ML) is applied to imaging biomarkers in neuro-oncology, in particular for diagnosis, prognosis, and treatment response monitoring. MATERIALS AND METHODS:The PubMed and MEDLINE databases were searched for articles published before September 2018 using relevant search terms. The search strategy focused on articles applying ML to high-grade glioma biomarkers for treatment response monitoring, prognosis, and prediction. RESULTS:Magnetic resonance imaging (MRI) is typically used throughout the patient pathway because routine structural imaging provides detailed anatomical and pathological information and advanced techniques provide additional physiological detail. Using carefully chosen image features, ML is frequently used to allow accurate classification in a variety of scenarios. Rather than being chosen by human selection, ML also enables image features to be identified by an algorithm. Much research is applied to determining molecular profiles, histological tumour grade, and prognosis using MRI images acquired at the time that patients first present with a brain tumour. Differentiating a treatment response from a post-treatment-related effect using imaging is clinically important and also an area of active study (described here in one of two Special Issue publications dedicated to the application of ML in glioma imaging). CONCLUSION:Although pioneering, most of the evidence is of a low level, having been obtained retrospectively and in single centres. Studies applying ML to build neuro-oncology monitoring biomarker models have yet to show an overall advantage over those using traditional statistical methods. Development and validation of ML models applied to neuro-oncology require large, well-annotated datasets, and therefore multidisciplinary and multi-centre collaborations are necessary.

SUBMITTER: Booth TC

PROVIDER: S-EPMC6927796 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Machine learning and glioma imaging biomarkers.

Booth T C TC Williams M M Luis A A Cardoso J J Ashkan K K Shuaib H H

Clinical radiology 20190729 1

<h4>Aim</h4>To review how machine learning (ML) is applied to imaging biomarkers in neuro-oncology, in particular for diagnosis, prognosis, and treatment response monitoring.<h4>Materials and methods</h4>The PubMed and MEDLINE databases were searched for articles published before September 2018 using relevant search terms. The search strategy focused on articles applying ML to high-grade glioma biomarkers for treatment response monitoring, prognosis, and prediction.<h4>Results</h4>Magnetic reson ...[more]

PMID: 31371027

Similar Datasets

Project description:A key factor in designing randomized clinical trials is the sample size required to achieve a particular level of power to detect the benefit of a treatment. Sample size calculations depend upon the expected benefits of a treatment (effect size), the accuracy of measurement of the primary outcome, and the level of power specified by the investigators. In this study, we show that radiomic models, which leverage complex brain MRI patterns and machine learning, can be utilized in clinical trials with protocols that incorporate baseline MR imaging to significantly increase statistical power to detect treatment effects. Akin to the historical control paradigm, we propose to utilize a radiomic prediction model to generate a pseudo-control sample for each individual in the trial of interest. Because the variability of expected outcome across patients can mask our ability to detect treatment effects, we can increase the power to detect a treatment effect in a clinical trial by reducing that variability through using radiomic predictors as surrogates. We illustrate this method with simulations based on data from two cohorts in different neurologic diseases, Alzheimer's disease and glioblastoma multiforme. We present sample size requirements across a range of effect sizes using conventional analysis and models that include a radiomic predictor. For our Alzheimer's disease cohort, at an effect size of 0.35, total sample size requirements for 80% power declined from 246 to 212 for the endpoint cognitive decline. For our glioblastoma multiforme cohort, at an effect size of 1.65 with the endpoint survival time, total sample size requirements declined from 128 to 74. This methodology can decrease the required sample sizes by as much as 50%, depending on the strength of the radiomic predictor. The power of this method grows with increased accuracy of radiomic prediction, and furthermore, this method is most helpful when treatment effect sizes are small. Neuroimaging biomarkers are a powerful and increasingly common suite of tools that are, in many cases, highly predictive of disease outcomes. Here, we explore the possibility of using MRI-based radiomic biomarkers for the purpose of improving statistical power in clinical trials in the contexts of brain cancer and prodromal Alzheimer's disease. These methods can be applied to a broad range of neurologic diseases using a broad range of predictors of outcome to make clinical trials more efficient.

Project description:Cancer pathology reflects disease progression (or regression) and associated molecular characteristics, and provides rich phenotypic information that is predictive of cancer grade and has potential implications in treatment planning and prognosis. According to the remarkable performance of computational approaches in the digital pathology domain, we hypothesized that machine learning can help to distinguish low-grade gliomas (LGG) from high-grade gliomas (HGG) by exploiting the rich phenotypic information that reflects the microvascular proliferation level, mitotic activity, presence of necrosis, and nuclear atypia present in digital pathology images. A set of 735 whole-slide digital pathology images of glioma patients (median age: 49.65 years, male: 427, female: 308, median survival: 761.26 days) were obtained from TCGA. Sub-images that contained a viable tumor area, showing sufficient histologic characteristics, and that did not have any staining artifact were extracted. Several clinical measures and imaging features, including conventional (intensity, morphology) and advanced textures features (gray-level co-occurrence matrix and gray-level run-length matrix), extracted from the sub-images were further used for training the support vector machine model with linear configuration. We sought to evaluate the combined effect of conventional imaging, clinical, and texture features by assessing the predictive value of each feature type and their combinations through a predictive classifier. The texture features were successfully validated on the glioma patients in 10-fold cross-validation (accuracy = 75.12%, AUC = 0.652). The addition of texture features to clinical and conventional imaging features improved grade prediction compared to the models trained on clinical and conventional imaging features alone (p = 0.045 and p = 0.032 for conventional imaging features and texture features, respectively). The integration of imaging, texture, and clinical features yielded a significant improvement in accuracy, supporting the synergistic value of these features in the predictive model. The findings suggest that the texture features, when combined with conventional imaging and clinical markers, may provide an objective, accurate, and integrated prediction of glioma grades. The proposed digital pathology imaging-based marker may help to (i) stratify patients into clinical trials, (ii) select patients for targeted therapies, and (iii) personalize treatment planning on an individual person basis.

Project description:Background: Microglia plays complex and crucial roles in multiple sclerosis (MS). This study aimed to explore the biological significance of microglia-associated genes in experimental autoimmune encephalomyelitis (EAE) . Methods: Differentially expressed genes (DEGs) were screened with six machine learning (ML) methods, which were also utilized to validate the microglia-associated DEGs in three public databases. ceRNA and Protein–protein interaction (PPI) network analyses were utilized to identify the interaction of the 6 novel biomarkers with other molecules. Then, CIBERSORT and single-sample gene set enrichment analysis (ssGSEA) were employed to quantify the relative abundance of each immune cell infiltration, respectively. qRT-PCR was performed to test the expression of key DEGs in murine models. Results: A total of 247 DEmRNA, 499 DElncRNAs and 269 DEcircRNAs were identified. With screening strategy of five ML algorithms, 6 DEmRNAs were obtained including NGP, HIST1H2BJ, PBLD1, MBLN3, CD180 and F10. Then the 6 DEmRNAs were used as a multigene signature to construct models to differentiate EAE from normal microglia, and AUC value for each model was greater than 0.8. The diagnostic value of these 6 DEmRNAs were identified and further verified by qRT-PCR. Then, differential expression for five out of these 6 DEmRNAs, namely NGP, HIST1H2BJ, PBLD1, MBLN3, and F10 were confirmed. Using PPI analysis, DEmRNAs frequently interacting with transcription factors (TFs), potential drugs and RBPs were identified. With immune cell infiltration analyses, we found EAE microglia presented high levels of immune infiltration, especially Nature Killer (NK) cells and CD8+ T cells. We also reported circRNA (circRNA_00638) was predicted to bind to 76 RBPs. Conclusions: We identified and validated 6 novel microglia related genes and developed a multigene signature with ML methods to confirm their ability to accurately diagnose and characterize biological alterations in EAE microglia. The six key DEmRNAs might also be latent targets for immunoregulatory therapy.

Dataset Information

Machine learning and glioma imaging biomarkers.

Publications

Machine learning and glioma imaging biomarkers.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets